Rezolute(US:RZLT) Globenewswire·2026-02-15 13:08Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [4]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, falling from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [6]. - The decline was triggered by the failure of the Phase 3 sunRIZE clinical trial for ersodetug, which did not meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events compared to placebo [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to discuss their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].